SpectraCure has initiated a joint project with the German company MedCom GmbH for the improving of SpectraCures technology for the treatment of prostate cancer with photodynamic therapy (PDT).
MedCom, based in Darmstadt, is the world leader in image-based control of minimally invasive procedures for diagnostics and treatment. The company delivers technical solutions to several major medical technology companies such as Hitachi Medical Systems and Elekta.
SpectraCures treatment method is based on optical fibres that leads laser light to the cancer tumour. High precision in the positioning of the fibres is a prerequisite for the SpectraCures IDOSE® system to deliver the correct dose to the tumour, without damaging the surrounding healthy tissues. The placement of needles with optical fibrer is currently done using ultrasound, which gives good accuracy but is time-consuming.
With the MedCom technology, a combination of MRI, ultrasound and 3D sensors is used, and the method is significantly faster than previous techniques. Thus, the time for patient treatment can be significantly reduced, which gives great benefits both to create acceptance of the SpectraCure treatment method and to reduce the cost of patient care in healthcare.
"The collaboration with MedCom gives SpectraCure great benefits," says the CEO of SpectraCure Masoud Khayyami. “We gain access to world-leading technologies that increase the commercial potential of the SpectaCure method. In the long term, we also see that cooperation can lead to purely clinical improvements in IDOSE® technology, with improved treatment results due to improved accuracy”.
Link www.medcom-online.de/home/
